Resalis Therapeutics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Resalis Therapeutics is a private, preclinical-stage biotech company pioneering non-coding RNA (ncRNA) therapeutics for metabolic diseases. Its lead program, RES-010, is a disease-modifying therapy for obesity and fatty liver disease, currently in Phase 1 clinical trials. The company leverages deep expertise in ncRNA biology and lipid metabolism to develop treatments that promise durable, fat-selective weight loss, as demonstrated in robust non-human primate studies. Resalis is positioning itself as a key player in the competitive but high-potential obesity and metabolic disorder treatment landscape.

Metabolic DisordersObesityFatty Liver Disease

Technology Platform

Platform for developing therapeutics based on non-coding RNA (ncRNA) modulation to regulate gene expression in metabolic pathways.

Opportunities

The global markets for obesity and MASLD therapies are enormous and growing, with high unmet need for durable, disease-modifying treatments.

Positive Phase 1 data for RES-010 could position the company for lucrative partnerships or financing to accelerate development.

Risk Factors

High clinical development risk as the novel ncRNA modality transitions to human trials.

Intense competition from large pharma in the metabolic space.

Financial dependency on raising capital as a private, pre-revenue company.

Competitive Landscape

Resalis competes in the crowded obesity/MASLD space dominated by GLP-1 agonists (e.g., Novo Nordisk, Eli Lilly) and a pipeline of novel mechanisms. Its key differentiation is the ncRNA approach aimed at durable, disease-modifying effects, but it must prove clinical superiority or complementary benefits to succeed.

More companies in RNA Therapeutics (non-mRNA) →More companies in Italy →